Ehrenstein Boris
Klinik und Poliklinik für Rheumatologie/Klinische Immunologie, Asklepios Klinikum Bad Abbach, 93077, Bad Abbach, Deutschland.
Z Rheumatol. 2020 Dec;79(10):1009-1017. doi: 10.1007/s00393-020-00915-y.
In the case of reduced cellular immunity the previously dormant varicella zoster virus (VZV) causes the characteristic belt-shaped vesicular exanthema of herpes zoster. The initial clinical symptoms of herpes zoster are often non-specific and may lead to initial misdiagnosis. A common complication of herpes zoster is postherpetic neuralgia (PHN) but secondary hematogenic dissemination is only rarely observed. In addition to general factors, such as advanced age and female gender, inflammatory rheumatic diseases and their immunosuppressive treatment are important risk factors for the occurrence of herpes zoster. Antiviral therapy initiated in the first 72 h after the onset of exanthema reduces acute symptoms and the risk of complications. The subunit inactivated vaccine, which has been available since 2018, is highly effective and relatively well-tolerated but randomized controlled trials in patients with drug-induced immunosuppression for inflammatory rheumatic diseases are still pending.
在细胞免疫功能降低的情况下,先前潜伏的水痘带状疱疹病毒(VZV)会引发带状疱疹典型的带状水疱性皮疹。带状疱疹的初始临床症状往往不具有特异性,可能导致最初的误诊。带状疱疹的常见并发症是带状疱疹后神经痛(PHN),但继发性血行播散很少见。除了年龄较大和女性等一般因素外,炎性风湿性疾病及其免疫抑制治疗是发生带状疱疹的重要危险因素。在皮疹出现后的72小时内开始抗病毒治疗可减轻急性症状并降低并发症风险。自2018年起可用的亚单位灭活疫苗高效且耐受性相对良好,但针对炎性风湿性疾病药物诱导免疫抑制患者的随机对照试验仍在进行中。